Feb 2023 $35 M No. 5 $10 to $50 million 3
VenatoRx Pharmaceuticals, Inc.: Raise no. 5, Feb 2023 × Investors in this round 3 investors had bought by the notice of Jul 13, 2023: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $35 M of $48 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $2,550,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Anthony J Meehan · Executive Officer Christopher J Burns · Executive Officer, Director Daniel C Pevear · Executive Officer Martin J Heidecker · Director Sergei J Petukhov · Director Timothy J Haines · Director Tomas C Heyman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Christopher J. Burns, President. Source: SEC Form D and 1 amendment, newest notice filed Jul 13, 2023. Read the notice at the SEC .
debt, options SEC Aug 2022 $25 M No. 4 $10 to $50 million 2
VenatoRx Pharmaceuticals, Inc.: Raise no. 4, Aug 2022 × Investors in this round 2 investors had bought by the notice of Dec 22, 2022: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $25 M of $25 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $1,000,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anthony J. Meehan · Executive Officer Christopher J. Burns · Executive Officer, Director Daniel C. Pevear · Executive Officer Ezra J. Felker · Executive Officer Timothy J. Henkel · Executive Officer Martin J. Heidecker · Director Michael C. Diem · Director Sergei J. Petukhov · Director Timothy J. Haines · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Christopher J. Burns, President. Source: SEC Form D and 1 amendment, newest notice filed Dec 22, 2022. Read the notice at the SEC .
equity SEC Mar 2022 $34 M No. 3 $10 to $50 million 3
VenatoRx Pharmaceuticals, Inc.: Raise no. 3, Mar 2022 × Investors in this round 3 investors had bought by the notice of Apr 4, 2022: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $34 M of $60 M offered; $26 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $2,400,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Anthony J. Meehan · Executive Officer Christopher J. Burns · Executive Officer, Director Daniel C. Pevear · Executive Officer Ezra J. Felker · Executive Officer Timothy J. Henkel · Executive Officer Martin J. Heidecker · Director Michael J. Diem · Director Sergei J. Petukhov · Director Timothy J. Haines · Director Vincent J. Milano · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Christopher J. Burns, President. Source: SEC Form D, newest notice filed Apr 4, 2022. Read the notice at the SEC .
equity SEC Jul 2017 $27 M No. 2 $10 to $50 million 47
VenatoRx Pharmaceuticals, Inc.: Raise no. 2, Jul 2017 × Investors in this round 47 investors had bought by the notice of Nov 5, 2018: 47 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $27 M of $47 M offered; $20 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $2,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Christopher J. Burns · Executive Officer, Director Daniel C. Pevear · Executive Officer Ezra J. Felker · Executive Officer Carlo J. Rizzuto · Director Michael J. Diem · Director Shelley J. Chu · Director Vincent J. Milano · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Christopher J. Burns, President. Source: SEC Form D and 1 amendment, newest notice filed Nov 5, 2018. Read the notice at the SEC .
equity, options SEC Nov 2013 $3 M No. 1 $2 to $10 million 59
VenatoRx Pharmaceuticals, Inc.: Raise no. 1, Nov 2013 × Investors in this round 59 investors had bought by the notice of Dec 4, 2013: 59 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken $15,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $175,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Christopher J. Burns · Executive Officer, Director Daniel C. Pevear · Executive Officer, Director Luigi J. Xerri · Executive Officer, Director Vincent J. Milano · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes payments made pursuant to the conversion of outstanding indebtedness”Signed by Christopher J. Burns, President. Source: SEC Form D, newest notice filed Dec 4, 2013. Read the notice at the SEC .
equity SEC